# Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

> **NCT07466927** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** SKB264
- **DRUG:** Pembrolizumab
- **DRUG:** SHR-1316

## Key facts

- **NCT ID:** NCT07466927
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2028-01-15
- **Final completion:** 2029-01-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07466927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07466927, "Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07466927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*